Deborah A. Robins - Concepedia

Concepedia

Author

Deborah A. Robins

Eli Lilly (United States)ORCID

Also Known As

D A Robins, D. A. Robins, DEBORAH A. ROBINS, Deborah A Robins, Deborah A. Robins, Deborah Robins, Robins, D.A., Robins, Deborah A.

43

Publications

3.6K

Citations

18

H-Index

26

Concepts

All Affiliations

Eli Lilly (United States)University of California San Diego Diabetes Care Center Tokushima University St. Josef-Hospital

DA

About

Deborah A. Robins is an author at Eli Lilly (United States) specializing in pharmacotherapy, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	942
2	Diabetes	2	2	897
3	Health Sciences	1	1	23
4	Public Health	1	1	22
5	Endocrinology	1	1	22

Deborah A. Robins

×

17

Publications

3.6K

Citations

17

H-Index

	Year	Citations
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Juan P. Frías, Michael A. Nauck, Joanna Van, The Lancet Metabolic SyndromeDiabetes ManagementDiabetesPharmacologyType 2	2018	762
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis Rohit Loomba, Mark L. Hartman, Eric Lawitz, New England Journal of Medicine	2024	611
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Sean Wharton, Thomas Blevins, Lisa Connery, New England Journal of Medicine	2023	378
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes Mark L. Hartman, Arun J. Sanyal, Rohit Loomba, Diabetes Care	2020	321
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Melissa K. Thomas, Amir Nikooienejad, Ross Bray, The Journal of Clinical Endocrinology & Metabolism	2020	300
A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density Robert R. Recker, Charles Benson, Toshio Matsumoto, Journal of Bone and Mineral Research	2014	288
Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens Juan P. Frías, Michael A. Nauck, Joanna Van, Diabetes Obesity and Metabolism	2020	198
The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes Jonathan M. Wilson, Amir Nikooienejad, Deborah A. Robins, Diabetes Obesity and Metabolism	2020	148
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study Juan P. Frías, Stanley H. Hsia, Sarah Eyde, The Lancet Diabetes ManagementMedicineDiabetesClinical TrialsType 2	2023	135
The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p <scp>ost hoc</scp> analysis Jonathan M. Wilson, Yanzhu Lin, Mengdie Luo, Diabetes Obesity and Metabolism	2021	113

Page 1